2. The correlation between increase in VS volume and audiologic deterioration during FU.
Results: Labyrinthine hypointensity on T2-weighted magnetic resonance images and complaints of hearing loss at presentation are predictive of a faster deterioration of hearing (p < 0.05). Growth during the first FU year predicts further growth. Vestibular schwannoma volume does not correlate with audiologic deterioration significantly.
on T2-weighted image of the affected labyrinth will result in a significant faster deterioration of hearing. Hearing loss was more profound, and hearing will deteriorate significantly faster in patients presenting with complaints of hearing loss. Significant growth during the first year of FU predicts further growth during FU. Sequential MRI cannot be substituted by audiologic examinations solely because increase in VS volume
does not correlate with audiologic deterioration significantly.”
“Objectives. GSI-IX molecular weight We aimed to investigate the association between the expression of phosphorylated Akt(Thr308) (p-Akt(Thr308)) in oral squamous cell carcinoma (OSCC) tissues and clinicopathological parameters of OSCC patients and to verify the validity Small molecule library research buy of p-Akt(Thr308) as a prognostic biomarker.
Study design. One hundred and ninety-one patients with OSCC were recruited for the study. We tested the expression of p-Akt(Thr308) by immunohistochemistry (IHC) with tissue microarray (TMA) and analyzed with digital pathology analysis software. The clinicopathological parameters of all patients were collected from follow-up.
Results. P-Akt(Thr308) was detected in 95.2% of OSCC patients. The expression of p-Akt(Thr308) was significantly correlated with local recurrence and five-year
survival rate. High expression of p-Akt(Thr308) in OSCC was associated with poor prognosis.
Conclusion. BTSA1 concentration P-Akt(Thr308) might be a candidate biomarker for the prediction of OSCC prognosis.”
The expression of Dkk-3, as a number of the Dkk family was different in different cancer. Because Dkk-3 encodes a secreted protein, we investigated whether the Dkk-3 protein is secreted into the sera of patients with gynecological cancer.
Material & Methods:
The levels of Dkk-3 protein were assessed by enzyme-linked immunosorbent assay in the sera of 104 patients with gynecological cancer: 36 with ovarian, 40 with cervical and 28 with endometrial cancers.
The serum levels of Dkk-3 protein in patients with ovarian cancer [25.54 (7.99) pg/mL] was lower than in normal individuals [42.08 (14.89) pg/mL] (P = 0.000). But serum levels of Dkk-3 protein in patients with cervical [166.39 (300.68) pg/mL] (P = 0.013) and endometrial cancers [73.64 (23.36) pg/mL] (P = 0.000) were higher than in normal individuals. The serum levels of Dkk-3 protein were associated with clinical stage in patients with cervical and endometrial cancers.